Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:21:22.916Z.
Calculation as of: 2026-10-06T16:21:22.916Z.
Quote observation: 2026-10-06T16:11:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dd458a7b7530169a13c79e175a6610edc18df904cb2af71895118b3708428af2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$59.92M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$60.78M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | $57.65M | N/A | N/A | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.98M | N/A | N/A | N/A | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $58.57M | N/A | N/A | N/A | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.81M | N/A | N/A | N/A | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.66M | N/A | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $59.92M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $54.74M | N/A | N/A | N/A | N/A |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.78M | N/A | N/A | N/A | N/A |
| Adicet Bio, Inc. (ACET)vs › | $60.95M | N/A | 108.20x | 108.20x | 108.20x |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.34M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
